Structured evidence table for Nattokinase Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Nattokinase Blood Pressure Randomized Trial | In order to reduce the risk of thrombosis, patients with atherosclerotic cardiovascular disease are often prescribed antiplatelet therapy. | 3 | Dobre Maria-Zinaida (2025) | Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks |
| Nattokinase Blood Pressure Randomized Trial | Nevertheless, platelet aggregation inhibition can also result in an increased bleeding risk, which is why the clinical approach must consider the benefit of single or dual antiplatelet treatments. | 3 | Dobre Maria-Zinaida (2025) | Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks |
| Nattokinase Blood Pressure Randomized Trial | The bleeding risk in atherosclerosis can arise from plaque rupture or the presence of intraplaque hemorrhage. | 3 | Dobre Maria-Zinaida (2025) | Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks |
| Nattokinase Blood Pressure Randomized Trial | 1 2 3 The development of atherosclerosis, an essential promoter of cardiovascular diseases and stroke via thrombus formation [], is supported by the interplay between platelets and endothelial cells []. | 3 | Dobre Maria-Zinaida (2025) | Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks |
| Nattokinase Blood Pressure Randomized Trial | Candidate treatments for long COVID: a narrative review of expert and patient-driven priorities | 4 | Baptista S (2026) | Candidate treatments for long COVID: a narrative review of expert and patient-driven priorities |
Source documents